New Data from Phase III SATURN Study Showed T...fter Initial Chemotherapy


OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) today announced further results from the Phase III SATURN study showing that Tarceva® (erlotinib) extended the survival of patients with advanced non-small cell lung cancer (NSCLC) when used as single agent, maintenance therapy in patients who did not progress following first-line treatment with platinum-based chemotherapy. As previously announced, the safety results in this study were consistent with what has been seen previously and there were no new or unexpected safety signals. Overall survival was a key secondary endpoint of the study and these new data were presented today at the 13th World Conference on Lung Cancer being held in San Francisco. ....

Advanced targeted therapies effective as first-line treatment for lung cancer

SAN FRANCISCO, August 1, 2009 — The world's top lung cancer specialists, medical professionals and researchers are convening this week in San Francisco, CA for the 13th World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC). According to a series of studies presented today at the WCLC, targeted therapies, as first-line treatment, have the potential to slow cancer growth and improve patient outcomes. Unlike traditional chemotherapy-based treatments, which destroy cancerous and non-cancerous cells alike, targeted therapies are designed to inhibit only cancer cell replication and tumor growth and are generally well tolerated by patients....

Experts find new targets to stop breast cancer

Hong Kong - One of the most aggressive forms of breast cancer may originate in the cells lining the mammary ducts, which can be targeted in the fight against the disease, experts in Australia say.

Basal breast cancers account for 20 percent of all breast cancers and are among the most aggressive. They occur in women carrying mutations of the tumour-suppressing gene BRCA1 and have long been thought to originate in breast stem cells.

However, a research team led by Jane Visvader and Geoff Lindeman from The Walter and Eliza Hall Institute of Medical Research in Australia has found that the real culprits may instead be pre-cancerous cells lining the mammary ducts.....

it is just amazing how many difrent types of cancer and how many difrent reserchers are looking for a cure in one way or another...

thanks for posting all these incredible articles..

personaly i think the reason we are seing cancer and other diseases in present day and age is the fact that medical science has up-ed the life expectancy over the past 300 years by alot

it is just stagering the amount of information still unknown about all these difrent cancers though

yes i agree it would be great if we could easly contact all those companies properly and let them know what we are doing here and the power of the distributed computing.

Unfortunatly alot of these companies are also out there for the money and may not make a fit with the processes here and requirements

Aspirin reduces chances of dying from colorectal cancer: Harvard scientists

Taking aspirin in a regular basis after being diagnosed with colon cancer has been found to reduce improve the chances of surviving the disease, Harvard researchers have found.

It has been suggested that regular use of aspirin can reduce the chances of developing colorectal cancer but now it has also been found that it reduces mortality in those who do have the cancer.
Daily low dose aspirin is often used to prevent heart attacks in people who have already had one or who are at high risk of having their first. It is also used after some forms of stroke and there is growing evidence of its use to prevent dementia and some cancers....